Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.

Saved in:
Bibliographic Details
Title: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease.
Authors: Kekre N; Division of Hematology, The Ottawa Hospital, Ottawa, ON, Canada., Kim HT; Department of Data Sciences, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA, USA., Hofer J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Ho VT; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Koreth J; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Armand P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Nikiforow S; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Gooptu M; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Romee R; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Alyea EP; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Nageshwar P; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Glotzbecker B; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., El-Jawahri A; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., DeFilipp Z; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Soiffer RJ; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Antin JH; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA., Chen YB; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Cutler C; Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. corey_cutler@dfci.harvard.edu.
Source: Bone marrow transplantation [Bone Marrow Transplant] 2021 May; Vol. 56 (5), pp. 1006-1012. Date of Electronic Publication: 2020 Sep 08.
Publication Type: Clinical Trial, Phase II; Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8702459 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5365 (Electronic) Linking ISSN: 02683369 NLM ISO Abbreviation: Bone Marrow Transplant Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1476-5365
DOI:10.1038/s41409-020-01049-0